新京报讯4月2日，奥园美谷科技股份有限公司(以下简称"ST美谷（000615）")发布公告，近日收到中国 证券监督管理委员会湖北监管局(以下简称"湖北证监局")下发的《关于对奥园美谷科技股份有限公司采 取警示函措施的决定》(【2025】21号，以下简称《警示函》)。 根据《警示函》，ST美谷存在以下违规事实：2024年11月18日，ST美谷披露的《关于前期会计差错更 正及追溯调整的公告》显示，2018年1月，ST美谷及全资子公司湖北金环新材料科技有限公司(以下简称 金环新材料)与湖北汉江产业投资有限公司(以下简称汉江产投)、襄阳国益国有资产经营有限责任公司等 共同发起设立湖北金环绿色纤维有限公司(以下简称金环绿纤)，金环绿纤于2018年2月完成工商注册登 记手续，其中汉江产投认缴注册资本9000万元，持有金环绿纤16.67%的股权。 湖北证监局认为，ST美谷的上述行为违反了《上市公司信息披露管理办法》(证监会令第40号)第二条第 一款、第三十条第一款第(三)项，《上市公司信息披露管理办法》(证监会令第182号)第三条第一款的规 定。根据《上市公司信息披露管理办法》(证监会令第40号)第五十九条、《上市公司信息 ...

4月1日晚间，塞力医疗连发三条公告。因未按期归还暂时补流的募集资金，塞力医疗被上海证交所通报 批评并被湖北证监局责令改正；因未按规定披露关联交易及大股东资金占用情况，未按规定披露重要合 同订立事项，塞力医疗遭湖北证监局行政处罚。 累计未归还募集资金4.68亿元 经查，塞力医疗于2024年7月27日前未按期归还暂时补流的募集资金8200万元，于2024年8月29日前未按 期归还暂时补流的募集资金3.74亿元，于2025年1月8日前未按期归还暂时补流的募集资金5000万元，并 导致2023年7月27日、2023年8月29日和2024年1月8日披露的信息"使用期限不超过12个月"与实际不符。 根据相关公告，塞力医疗于2024年12月30日归还800万元至募集资金专用账户，于2025年2月27日归还 3000万元至募集资金专用账户。截至2025年2月28日，塞力医疗累计未归还募集资金合计为4.68亿元。 上海证交所认为，塞力医疗将多笔闲置募集资金用于暂时补充流动资金，均未在规定期限内及时归还， 且所涉金额较大，上述行为违反了相关规定；时任董事长温伟作为公司主要负责人，时任总经理王政作 为公司日常经营管理的具体负责人， ...

Core Viewpoint - The company, Selys Medical Technology Group Co., Ltd., has received an administrative penalty notice from the Hubei Regulatory Bureau of the China Securities Regulatory Commission (CSRC) due to violations related to information disclosure and related party transactions. Group 1: Administrative Penalty Details - The company and its actual controller, Wen Wei, are under investigation for failing to disclose related party transactions and the occupation of funds by major shareholders [2][3][4] - From 2020 to the first half of 2022, the actual controller arranged for the company to transfer funds to a related party, constituting a violation of disclosure obligations [3][6] - The total amount of funds occupied during this period was approximately 1.213 billion yuan in 2020, 1.3225 billion yuan in 2021, and 1.1465 billion yuan in the first half of 2022, with the amounts representing 7.48%, 7.33%, and 6.58% of the company's audited net assets respectively [3][4] Group 2: Violations and Responsibilities - The company failed to follow the required procedures for related party transactions and did not disclose these transactions until April 2023 [4][5] - Wen Wei, as the chairman and actual controller, is identified as the main responsible person for the violations, along with other executives who also failed to ensure proper disclosure [6][7][8] - The company is facing a total fine of 600 million yuan for the violations, with specific penalties for Wen Wei and other executives ranging from 30 million to 550 million yuan [15][16][17] Group 3: Impact on Company Operations - The company stated that the violations do not trigger mandatory delisting conditions and that its operations remain normal as of the announcement date [18] - The company has expressed its commitment to improving internal governance and compliance to prevent future violations [18][22] - The company is required to submit a rectification report within 30 days of receiving the penalty notice, detailing measures taken to address the violations [22]

| 处分， 交易所1年内不接受国宏工具提交的上市申请； | | --- | | 对IPO项目保荐机构申万宏源及两名保代予以纪律处分， 交易所6个月内不接受两名保代签字的发行上市申请文件及信息披露文件； | | 对IPO项目申报会计师公证天业及两名签字注册会计师予以纪律处分， 交易所6个月内不接受两名会计师签字的发行上市申请文件及信息披露文件； | | 对IPO项目申报律师上海通力及三名签字律师予以纪律处分。 | | 据查明，该公司在首次公开发行股票申请过程中，未准确披露研发人员数量及研发投入金额，累计多计研发投入 727.84 万元；未经审议决策程序代控股股东对外履 | | 延展阅读： 《又一科创板IPO终止！曾被抽中现场检查，两科创指标踩线达标，是否有水份？》 | | 行对赌回购义务，未充分披露公司治理存在的缺陷；未准确披露实际控制人的一致行动人；未充分计提应收账款坏账准备。 | 关于对国宏工具系统（无锡）股份有限公司及相关责任人予以纪律处分的决定 当事人： 国宏工具系统（无锡）股份有限公司； 吴健新，国宏工具系统（无锡）股份有限公司时任董事长； 吕显豹，国宏工具系统（无锡）股份有限公司时任总经理； 姜雨康 ...

截至今日收盘，皇氏集团上涨1.05%，总市值33.37亿元；美晨科技下跌2.46%，总市值28.55亿元。 3月31日晚间，皇氏集团（002329.SZ）、美晨科技（300237.SZ）双双公告称，公司于近日收到证监会下发的《立案告知书》，因公司涉嫌信息披露违法违 规，根据相关法律法规，证监会决定对公司立案。 皇氏集团曾收监管函，年报披露也存在问题 在上述公告中，皇氏集团称，公司自查发现，2019年原子公司皇氏数智有限公司与泰安市东岳财富股权投资基金有限公司签订《合伙协议》及《补充协 议》，公司未及时披露《补充协议》，直至2023年11月才对《补充协议》主要内容进行披露。 皇氏集团表示，目前公司生产经营正常，公司被立案调查事项不会对生产经营产生重大影响。立案调查期间，公司将积极配合中国证监会工作，并履行信息 披露义务。 公开资料显示，皇氏集团成立于2001年，2010年1月在深交所上市，是国内A股第四家上市的乳品企业。据官网介绍，公司已成长为我国水牛奶产业规模最 大、技术实力最强的龙头企业。 值得注意的是，2024年年底，皇氏集团曾收到深交所出具的监管函。监管函同样提及，皇氏集团对上述事项的信息披露不完整、不 ...

Core Viewpoint - The Shenzhen Stock Exchange issued a regulatory letter to Zhongshan United Optoelectronics Technology Co., Ltd. for inaccurate and untimely information disclosure regarding its "heavy-duty quadruped robot" business, raising concerns about the company's governance and financial health [2] Financial Performance - In the first half of 2024, the company's revenue reached 848 million yuan, a year-on-year increase of 5.75%, but net profit declined by 27.67% to 28.25 million yuan, with a non-recurring net profit drop of 33.32% [3] - The decline in profitability is attributed to a significant increase in R&D expenses, which rose by 34.28% to 104 million yuan, and intensified competition in the consumer electronics market affecting gross margins [3] - The company's operating cash flow turned negative, with a net outflow of 53.81 million yuan, a decrease of 61 million yuan year-on-year, and free cash flow worsened to -37.30 million yuan, indicating increased pressure on the cash flow [3] Financial Health - As of the end of Q3 2024, the company's debt-to-asset ratio rose to 42.43%, an increase of 6.67 percentage points compared to the same period in 2023, with long-term borrowings increasing by 48.84% [4] - Interest-bearing debt ratio increased to 17.64%, while inventory value reached 441 million yuan, accounting for 27.23% of net assets, a 20.29% increase from the end of the previous year [4] - If market demand does not meet expectations, liquidity risks may further escalate [4] Business Performance - The company maintains strong competitiveness in traditional sectors such as security monitoring and intelligent driving, with high-end lens products dominating the security market and improving production capacity in vehicle-mounted lenses [5] - However, the failure of the robot project highlights deficiencies in the company's technological reserves and commercialization capabilities in emerging fields, with high R&D investments not translating into actual revenue [5] Future Outlook - The Shenzhen Stock Exchange has mandated the company’s board to immediately rectify and enhance compliance in information disclosure [5] - The company plans to release its 2024 annual report on April 21, 2025, with market focus on debt structure optimization, cash flow improvement, and adjustments in emerging businesses [5] - In the short term, the company needs to restore investor confidence, while long-term sustainability will depend on balancing innovation investments with profitability in its optical core business [5]

Core Viewpoint - Zhejiang Tailin Biotechnology Co., Ltd. received a warning letter from the Zhejiang Securities Regulatory Bureau due to information disclosure violations, raising concerns about the company's operational compliance and financial stability [1][2]. Group 1: Information Disclosure Violations - The Zhejiang Securities Regulatory Bureau found that Tailin Biotechnology failed to disclose issues related to insufficient production capacity of fundraising projects, land use changes, and investment pauses in joint ventures [2]. - The company and its responsible personnel, including the chairman and CFO, were held accountable for these violations, which contravened the regulations on timely and accurate information disclosure [2][3]. - Tailin Biotechnology acknowledged the issues raised in the warning letter and committed to improving compliance and information disclosure practices [3]. Group 2: Previous Regulatory Issues - This warning letter is not the first regulatory issue for Tailin Biotechnology; the company faced fines for violations of fire safety and environmental regulations in the past [4]. - The incidents highlight the importance of adhering to legal and regulatory requirements, especially in the context of ongoing reforms in the registration system [4]. Group 3: Financial Performance - Tailin Biotechnology's financial performance has shown signs of decline, with revenues of 374 million yuan, 270 million yuan, and 242 million yuan for 2022, 2023, and the first three quarters of 2024, respectively, reflecting year-on-year changes of 32.00%, -27.82%, and 19.37% [5]. - The net profit attributable to shareholders also decreased significantly, with figures of 80 million yuan, 20 million yuan, and 11 million yuan for the same periods, showing year-on-year changes of 25.43%, -75.32%, and -46.91% [5]. - The company has been exploring the cell therapy equipment sector but announced a delay in the project timeline for the "Cell Therapy Industrialization Equipment Manufacturing Base Project" due to changes in implementation methods and macroeconomic factors [5].